The IMF sponsored a Corporate Friday Symposium preceding the 46^th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The CME-certified symposium entitled, “Controversies in Myeloma Management: Diagnosis, Initial Treatment, and the Relapsing Patient” was jointly sponsored by the IMF and the Institute for Continuing Healthcare Education, an ACCME-accredited provider of continuing medical education.

	CONTROVERSIES IN MYELOMA MANAGEMENT: Introduction Diagnosis, Initial Treatment and the Relapsing Patient
	PRELIMINARY CASE EVALUATION: AN INTERACTIVE ASSESSMENT OF AUDIENCE TREATMENT OPTIONS By Morie A. Gertz, MD
	NEW APPROACHES TO MYELOMA STAGING AND FRONT-LINE TREATMENT SELECTION By Brian G.M. Durie, MD
	CURRENT U.S. EXPERIENCE WITH TRANSPLANTATION AND MANAGEMENT OF THE NEWLY DIAGNOSED PATIENT By Bart Barlogie, MD, PhD
	CURRENT EUROPEAN EXPERIENCE WITH TRANSPLANTATION AND MANAGEMENT OF THE NEWLY DIAGNOSED PATIENT By Gareth J. Morgan, MD
	EVALUATION OF THE PATIENT IN INITIAL RELAPSE AND SELECTION OF SECOND-LINE THERAPEUTIC OPTIONS By James D. Cavenagh, MD
	OVERVIEW OF KYPHOPLASTY IN THE MANAGEMENT OF SPINAL TUMORS By Sigurd Berven, MD
	PRELIMINARY CASE EVALUATION REVISITED By Morie A. Gertz, MD